Natera has developed a blood test that provides pregnant women with the best-in-class information regarding their pregnancy. When a woman is pregnant, some fetal DNA begins to circulate in her blood stream. As early as 9 weeks in her pregnancy she can get the Panorama prenatal test which can screen for a variety of conditions, including Down syndrome. Different from invasive procedures such as an amniocentesis, the Panorama prenatal test relies on a simple blood draw and poses no risk of miscarriage.
Accurate and Comprehensive Non-invasive Prenatal Testing — Now also able to identify triploidy
The Panorama prenatal test screens for aneuploidies of chromosomes 21, 18, 13, X and Y — and now also triploidy — with unparalleled clinical results. Panorama uses a proprietary approach utilizing single nucleotide polymorphisms (SNPs), which yields consistently accurate calls across all conditions screened for. Panorama results come in the form of a personalized risk score enabling physicians to manage followup specific to each patient.
The Panorama prenatal test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).